Novartis’ asthma candidate beats GlaxoSmithKline’s in Phase 2 trial
Category: #health  By Sunil Hebbalkar  Date: 2019-05-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis’ asthma candidate beats GlaxoSmithKline’s in Phase 2 trial
  • The clinical study linked Novartis’ QVM149 to significant lung function improvements.
  • If a Phase 3 trial confirms the results, Novartis intends to unveil the product in 2020.

Novartis International AG (Novartis), a renowned Swiss multinational pharmaceutical firm, has reportedly announced that its triple-combination asthma drug, QVM149 has defeated Advair, developed by British pharmaceutical firm, GlaxoSmithKline (GSK) in a Phase 2 clinical trial.

Reports cite, the clinical study linked Novartis’ QVM149 to statistically significant lung function improvements, which led the company to promote its potential to improve the outcomes of uncontrolled asthma.

According to reliable reports, Novartis’ QVM149 was compared with GSK’s Advair & placebo and results suggested that glycopyrronium bromide, indacaterol acetate and mometasone furoate; the triplets, when inhaled through the Breezhaler device performed substantially better in improving the patient’s lung function.

Novartis’ second clinical trial also assessed whether the triplets’ effects vary depending upon the time it was administered during the day. The assessment found that the triplet outperformed the placebo regardless of the time it was administered; the morning or the evening.

Advair’s initial success made it into a blockbuster product. Now, the drug faces generic competition, however, there is still scope for branded products that further improves on it to boost sales, which has led Novartis to endorse QVM149 as a potential billion-dollar drug.

Despite beating Advair, Novartis’ QVM149 would have to come through in its ongoing Phase 3 trials to properly deliver on its recent hype. Meanwhile, the Swiss pharmaceutical firm is fleshing out evidence to support the triplet using data from previous phase trials.

According to reports, given that the triplet’s safety & tolerability outcomes are clean, the company thinks that the clinical data places QVM149 a step closer to establishing itself as a once-daily asthma treatment option for approximately one-third of asthma patients that are being served poorly by existing therapies.

If the Phase 3 trial confirms the results, Novartis intends to unveil the product in 2020 and promote it as a blockbuster in the upcoming years.

Source Credit: https://www.fiercebiotech.com/biotech/novartis-asthma-triplet-beats-gsk-s-advair-phase-2-trial

https://endpts.com/novartis-drums-up-anticipation-for-blockbuster-to-be-with-phii-data-on-asthma-drug/



About Author

Sunil Hebbalkar

Email: [email protected]   

Sunil Hebbalkar

Sunil Hebbalkar develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development departm...

Read More

More News By Sunil Hebbalkar

Altaire’s veterinary ophthalmic products recalled due to QA concerns
Altaire’s veterinary ophthalmic products recalled due to QA concerns
By Sunil Hebbalkar

  • Altaire Pharmaceuticals recalls specific product/lots of ophthalmic drugs created for Dechra Veterinary Products, due to sterility concerns.
     
  • No adverse effects have been reported yet.
Biogen & Invitae introduce SMA STAT test for faster genetic testing
Biogen & Invitae introduce SMA STAT test for faster genetic testing
By Sunil Hebbalkar

Global biotechnology expert Biogen Inc. and advanced genetics leader Invitae Corporation have reportedly announced their new rapid-turnaround test for genetic testing in the diagnosis for SMA (spinal muscular atrophy)....

Target launches flagship food label with more than 2000 products
Target launches flagship food label with more than 2000 products
By Sunil Hebbalkar

US based retailer Target has reportedly announced the launch of its new private grocery brand, Good & Gather.

Starting next month, Target stores across the United States will st...